Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab (GMAB) reported updated Phase 2 trial results for petosemtamab in metastatic colorectal cancer, showing 75% and 67% objective response rates in first- and second-line settings, respectively. The data supports ongoing Phase 3 trials and was presented at ESMO Congress 2026. Petosemtamab is an investigational bispecific antibody targeting EGFR and LGR5.

Original reporting
Published Oct 25, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
9/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The Phase 2 results provide a tangible efficacy signal that could de‑risk the upcoming Phase 3 trials and affect the company's valuation.

02

Market read

First‑time disclosure of strong Phase 2 efficacy data; likely catalyst for Genmab and related oncology biotech stocks.

03

What to watch

Long‑term durability and comparative efficacy versus existing EGFR therapies remain uncertain.

Relevance 9/10Novelty 9/10Timing: post‑ESMO presentation today

Background

Genmab is a Copenhagen‑based biotech developing bispecific antibodies; petosemtamab targets EGFR and LGR5 in colorectal cancer.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab announced updated Phase 2 follow‑up data showing 75% objective response rate in first‑line metastatic colorectal cancer patients.

Expected impact

likely upward pressure as market prices in the strong response rates.

Evidence & confidence

The data are a first‑time disclosure of high efficacy, a material catalyst for a biotech with an upcoming Phase 3 program.

Market effects

Boosts sentiment for oncology biotech stocks and may raise valuations of similar bispecific antibody programs.

European markets could see a modest rally in biotech indices following the announcement.

Adds positive momentum to the global biotech sector, potentially influencing investor appetite for late‑stage trial news.

Counterpoint

Skeptics may argue the sample size is limited and safety signals could temper enthusiasm.

Key entities

  • Genmab A/S

    Biotech firm developing petosemtamab.

  • Petosemtamab (GEN1158)

    Investigational bispecific antibody targeting EGFR and LGR5.

Related articles

$GMABHighAI 8/10

Genmab (GMAB) Q3 2026 Earnings Call Transcript

Genmab reported positive phase III trial results for Epkinly, Rina-S, and petosemtamab, with Epkinly showing a hazard ratio of 0.49 in the EPCORE DLBCL-2 trial. Sales for Epkinly and Tivdak grew 47% and 9% year-over-year, respectively, to $491M and $131M in the first nine months of 2026. The company is preparing for potential launches in early lines of DLBCL and other indications.

$GMABMedAI 8/10

Why is Genmab stock sliding today?

Genmab (GMAB) shares fell 4.9% after Q3 revenue of $1.19B missed estimates, though EPS beat. Epkinly sales grew 47% but lagged Jyske Bank's forecast. Full-year guidance remained unchanged, disappointing some analysts. Higher costs reduced net profit. The company maintained its revenue and earnings outlook but did not raise it, despite recent clinical trial successes.